Introduction:

Pulmonary arterial hypertension (PAH) is a low prevalence condition for which there is very little information in Peru. Various studies indicate that it generates significant costs for health systems in the world.

Objective:

To establish the economic burden of PAH in the Peruvian context.

Methods:

Information on the use of health resources was collected through consultations with clinical experts and opinion leaders. The cost information was obtained from two tariff manuals and the Observatory of Pharmaceutical Products.

Results:

The experts indicated that about 68% of the patients were in an intermediate stage of the disease and that sequential combination therapy is predominant in the FC III and FC IV stages, compared to earlier stages. The annual cost of PAH treatment in Peru was $ 14,842 USD (S / 25,885), where the main item were drugs (81.72%), followed by diagnosis (8.96%) and outpatient follow-up (5, 75%).

Conclusion:

Information on pulmonary arterial hypertension in Peru is critical for decision-makers due to the high economic impact. Furthermore, studies in this therapeutic area are relevant for disseminating knowledge of the disease to different health professionals.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )